<scp>SV2A</scp> expression in blood cells as a possible biomarker candidate for levetiracetam treatment response
Naive CD8+ T cell-specific SV2A MFI ratio may represent a potential indicator of treatment response for levetiracetam. Pending further validation, its stability and accessibility suggest that it could potentially support treatment decisions and help to reduce ineffective drug trials.
Authors
- Mathias Linnerbauer (ORCID: https://orcid.org/0000-0002-5528-5141)
- Jeanne Cuny
- Johannes Lang (ORCID: https://orcid.org/0000-0001-9019-9081)
- HM Hamer
- Veit Rothhammer
Institutions
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Universitätsklinikum Erlangen (DE)
- Comprehensive Cancer Center Erlangen (DE)
Publication Details
- Journal
- Epilepsia
- Published
- 2026-02-04
- DOI
- https://doi.org/10.1002/epi.70122
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00